We are live on ! Find out more
EVOK

Evoke Pharma
EVOK

Delisted

EVOK was delisted on the 16th of December, 2025.

Back to rankings

15 hedge funds and large institutions have $1.93M invested in Evoke Pharma in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,588% more capital invested

Capital invested by funds: $71.8K → $1.93M (+$1.86M)

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

50% more funds holding

Funds holding: 10 → 15 (+5)

35.26% more ownership

Funds ownership: 2.05% → 37.3% (+35%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

Holders
15
Holders Change
+5
Holders Change %
+50%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
2
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACM
AIGH Capital Management
Maryland
+$599K
2
BL
Bleichroeder LP
New York
+$584K
3
ACM
Altium Capital Management
New York
+$513K
4
NCM
Nantahala Capital Management
Connecticut
+$478K
5
Goldman Sachs
Goldman Sachs
New York
+$9.54K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$1.28K
2
BlackRock
BlackRock
New York
-$8
3
FDCDDQ
Federation des caisses Desjardins du Quebec
Quebec, Canada
-$2

EVOK Hedge Fund Activity: Q1 2024 in Review

15 of the 6,961 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q1 2024, worth a combined $1.93M — up 2,588% from $71.8K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new EVOK positions and 1 closed out — a net gain of 5 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was AIGH Capital Management, opening a new position worth an estimated $599K. The largest seller was UBS Group, cutting an estimated $1.28K.

  • 15 institutional investors held Evoke Pharma (EVOK) as of Q1 2024, up from 10 in Q4 2023.
  • Funds reported $1.93M of Evoke Pharma stock for Q1 2024, up 2,588% quarter-over-quarter.
  • 6 funds opened new Evoke Pharma positions in Q1 2024 and 1 closed out, a net change of +5 holders.
  • The largest Evoke Pharma buyer in Q1 2024 was AIGH Capital Management, an estimated $599K added.
  • The largest Evoke Pharma seller in Q1 2024 was UBS Group, an estimated $1.28K sold.

Based on aggregated 13F filings for Q1 2024.